Identifying Sex Differences in Lung Adenocarcinoma Using Multi-Omics Integrative Protein Signaling Networks DOI Creative Commons
Chen Chen, Enakshi Saha, Jonas Fischer

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 7, 2025

Abstract Lung adenocarcinoma (LUAD) exhibits differences between the sexes in incidence, prognosis, and therapy, suggesting underexplored molecular mechanisms. We conducted an integrative multi-omics analysis using Clinical Proteomic Tumor Analysis Consortium (CPTAC) The Cancer Genome Atlas (TCGA) datasets to contrast transcriptomes proteomes sexes. used TIGER analyze TCGA-LUAD expression data found sex-biased activity of transcription factors (TFs); we PTM-SEA with CPTAC-LUAD proteomics kinase activity. combined these construct a kinase-TF signaling network discovered druggable pathways linked cancer-related processes. also significant sex biases clinically relevant TFs kinases, including NR3C1, AR, AURKA. Using PRISM drug screening database, identified potential sex-specific drugs, such as glucocorticoid receptor agonists aurora inhibitors. Our findings emphasize importance considering methods discover personalized cancer therapies.

Language: Английский

Identifying Sex Differences in Lung Adenocarcinoma Using Multi-Omics Integrative Protein Signaling Networks DOI Creative Commons
Chen Chen, Enakshi Saha, Jonas Fischer

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 7, 2025

Abstract Lung adenocarcinoma (LUAD) exhibits differences between the sexes in incidence, prognosis, and therapy, suggesting underexplored molecular mechanisms. We conducted an integrative multi-omics analysis using Clinical Proteomic Tumor Analysis Consortium (CPTAC) The Cancer Genome Atlas (TCGA) datasets to contrast transcriptomes proteomes sexes. used TIGER analyze TCGA-LUAD expression data found sex-biased activity of transcription factors (TFs); we PTM-SEA with CPTAC-LUAD proteomics kinase activity. combined these construct a kinase-TF signaling network discovered druggable pathways linked cancer-related processes. also significant sex biases clinically relevant TFs kinases, including NR3C1, AR, AURKA. Using PRISM drug screening database, identified potential sex-specific drugs, such as glucocorticoid receptor agonists aurora inhibitors. Our findings emphasize importance considering methods discover personalized cancer therapies.

Language: Английский

Citations

0